menu
    • menu
    [{"orgOrder":0,"company":"Sichuan Biokin Pharmaceutical","sponsor":"Sichuan Biokin Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"177-Lu BL-ARC001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sichuan Biokin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Biokin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Sichuan Biokin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Biokin Pharmaceutical","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"SHR-3045","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Sichuan Biokin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Biokin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sichuan Biokin Pharmaceutical \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Sichuan Biokin Pharmaceutical

    Menu

    Sichuan Biokin Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sichuan Biokin Pharmaceutical

                            China arrow
                            OTS 2025
                            Not Confirmed

                            Sichuan Biokin Pharmaceutical

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu BL-ARC001

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Sichuan Biokin Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            C-Ray Therapeutics (Chengdu) Co., Ltd Congratulates Partner Biokin Pharmaceutical on NMPA IND Approval of Firs...

                            Details : 177-Lu BL-ARC001 is a Radiolabeled Compound drug candidate, which is currently being evaluated in IND Enabling clinical studies for the treatment of Neoplasms.

                            Product Name : 177-Lu BL-ARC001

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            October 11, 2025

                            Lead Product(s) : 177-Lu BL-ARC001

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Sichuan Biokin Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sichuan Biokin Pharmaceutical

                            China arrow
                            OTS 2025
                            Not Confirmed

                            Sichuan Biokin Pharmaceutical

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SHR-3045

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Recipient : Jiangsu Hengrui Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of SHR-3045 in Healthy Subjects

                            Details : SHR-3045 is a large molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Arthritis, Rheumatoid.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 01, 2025

                            Lead Product(s) : SHR-3045

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Recipient : Jiangsu Hengrui Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth